Efficiency and safety of daclatasvir in treatment of chronic hepatitis C: A meta-analysis / 解放军医学杂志

ABSTRACT

Objective To evaluate the efficacy and safety of daclatasvir in treatment of chronic hepatitis C (CHC). Methods Articles regarding treatment and safety of CHC were retrieved from PubMed, EMBASE, The Cochrane Central Register of Controlled Trials, Chinese Journals Full-text Database (CNKI, China National Knowledge Infrastructure), and WanFang Digital Journal Full-text Database to collect clinical RCTs (randomized controlled trials) for CHC treated by daclatasvir. Meta-analysis was performed by using Review Manager 5.3. Results A total of six RCTs including 1100 patients met the inclusion criteria. Metaanalysis results were as follows. 1) The overall RVR (rapid virological response), cEVR (complete early virological response) and SVR24 (sustained virological response at post-treatment week 24) rates were significantly higher in daclatasvir group than in control group. 2) The RVR, cEVR, and SVR24 rates were significantly higher in daclatasvir (60mg/d) group than in control group. 3) The RVR and cEVR rates were significantly higher in daclatasvir (10mg/d) group than in control group, but no significant difference existed between the two groups in the SVR24 rate. 4) No significant differences were found in nonspecific adverse events, liver function, hematologic system or skin between daclatasvir and control groups. Conclusion Daclatasvir is effective and safe in treatment of CHC, and daclatasvir 60mg/d is a better choice as compared with daclatasvir 10mg/d.